BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide — sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val — derived from a cytoprotective protein first identified in gastric juice.
Across published in-vitro and animal-model studies, BPC-157 has been examined for its effects on angiogenesis (the growth of new blood vessels), the migration of tendon and ligament fibroblasts, and the integrity of the gut lining. A recurring theme in this work is modulation of the nitric-oxide (NO) system and of vascular endothelial growth factor (VEGF) signalling as the proposed mechanisms.
The important caveat: this evidence is preclinical. BPC-157 is not an approved medicine in the UK or anywhere else, and human clinical data are limited. It is handled purely as a research compound.
For lab work, identity and purity are everything: each Vosberg vial is a lyophilised powder, independently HPLC-tested to at least 99% purity, with identity confirmed by mass spectrometry. Keep the sealed vial below −18°C until use.
This article is for educational and research-reference purposes only. It is not medical advice. All products are supplied strictly for in-vitro laboratory research use, not for human or veterinary consumption.